HK1111085A1 - Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of huntington' s disease - Google Patents

Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of huntington' s disease

Info

Publication number
HK1111085A1
HK1111085A1 HK08105582.5A HK08105582A HK1111085A1 HK 1111085 A1 HK1111085 A1 HK 1111085A1 HK 08105582 A HK08105582 A HK 08105582A HK 1111085 A1 HK1111085 A1 HK 1111085A1
Authority
HK
Hong Kong
Prior art keywords
dihydrotetrabenazine
huntington
cis
symptoms
disease
Prior art date
Application number
HK08105582.5A
Other languages
English (en)
Inventor
Robert Tridgett
Thierry Filloux
Original Assignee
Cambridge Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Lab Ireland Ltd filed Critical Cambridge Lab Ireland Ltd
Publication of HK1111085A1 publication Critical patent/HK1111085A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK08105582.5A 2005-07-14 2008-05-20 Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of huntington' s disease HK1111085A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0514501.6A GB0514501D0 (en) 2005-07-14 2005-07-14 Pharmaceutical compounds
PCT/GB2006/002593 WO2007007105A1 (en) 2005-07-14 2006-07-13 Use of 3,1ib-cis-dihydrotetrabenazine for the treatment of symptons of huntington' s disease

Publications (1)

Publication Number Publication Date
HK1111085A1 true HK1111085A1 (en) 2008-08-01

Family

ID=34897233

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08105582.5A HK1111085A1 (en) 2005-07-14 2008-05-20 Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of huntington' s disease

Country Status (24)

Country Link
US (1) US20080319000A1 (ja)
EP (2) EP2027861B1 (ja)
JP (1) JP2009501202A (ja)
KR (1) KR20080030666A (ja)
CN (1) CN101282726A (ja)
AT (2) ATE522215T1 (ja)
AU (1) AU2006268098B2 (ja)
CA (1) CA2615077A1 (ja)
CY (1) CY1108653T1 (ja)
DE (1) DE602006002982D1 (ja)
DK (1) DK1885363T3 (ja)
ES (1) ES2314931T3 (ja)
GB (1) GB0514501D0 (ja)
HK (1) HK1111085A1 (ja)
HR (1) HRP20080677T3 (ja)
ME (1) ME01629B (ja)
NZ (1) NZ565522A (ja)
PL (1) PL1885363T3 (ja)
PT (1) PT1885363E (ja)
RS (1) RS50626B (ja)
RU (1) RU2409365C2 (ja)
SI (1) SI1885363T1 (ja)
WO (1) WO2007007105A1 (ja)
ZA (1) ZA200800905B (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
EA018378B1 (ru) 2006-11-08 2013-07-30 Ньюрокрайн Байосайенсиз, Инк. ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
JP2013501810A (ja) * 2009-08-12 2013-01-17 ヴァリーント インターナショナル(バルバドス)エスアールエル 医薬組成物
EP3351247A1 (en) * 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2012095548A2 (es) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compuestos para el tratamiento de enfermedades neurodegenerativas
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
EP3606530A2 (en) * 2017-04-01 2020-02-12 Adeptio Pharmaceuticals Limited Dihydrotetrabenazine for use in the treatment a movement disorder
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201808464D0 (en) * 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
EP3999051A4 (en) * 2019-07-16 2023-08-02 Rush University Medical Center USE OF A COMPOSITION CONTAINING BENZOATE FOR TREATING NEURODEGENERATIVE DISORDERS

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2843591A (en) * 1958-07-15 Method for preparing same
US3009918A (en) * 1961-11-21 Chz ch
US3053845A (en) * 1962-09-11 Benzofykedocolines
US3095419A (en) * 1963-06-25 Process for preparing z-oxo-j-
US2954382A (en) * 1960-09-27 Xpreparation of hexahydrobenzoquinol-
US3079395A (en) * 1963-02-26 Novel z-oxq-benzoquinoliaine
US3314966A (en) * 1967-04-18 Substituted benzo[a]quinolizines
US3209005A (en) * 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
US3132147A (en) * 1964-05-05
US2830993A (en) * 1958-04-15 Quinolizine derivatives
US3159638A (en) * 1964-12-01 Xcha-chj
US3123609A (en) * 1964-03-03 Benzo
US3045021A (en) * 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
GB999092A (en) * 1959-11-24 1965-07-21 Wellcome Found Method for making benzo(a)-quinolizine derivatives
US3375254A (en) * 1961-09-29 1968-03-26 Burroughs Wellcome Co Manufacture of 1, 2, 3, 4, 6, 7-hexahydro-2-oxo-11bh-benzo(a)quinolizines
US3105079A (en) * 1961-12-29 1963-09-24 Pfizer & Co C 10-aminobenzopyridocolines
US3390152A (en) * 1965-10-21 1968-06-25 Abbott Lab 9, 10-alkoxy-3-alkyl-2, 2-(dithiosubstituted)-benzoquinolizines
JPS4836303B1 (ja) * 1968-12-27 1973-11-02
US3635986A (en) * 1969-12-22 1972-01-18 Miles Lab 2-substituted amino-hexahydrobenzo(a)quinolizines
YU264675A (en) * 1974-10-23 1982-05-31 Chinoin Gyogyszer Es Vegyeszet Process for obtaining benzo (a)-quinolizidine derivatives
GB1513824A (en) * 1975-05-22 1978-06-14 Wyeth John & Brother Ltd 1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine derivative
US4133812A (en) * 1975-11-21 1979-01-09 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Process for producing benzo (a) quinolizine derivatives
US4304913A (en) * 1978-11-20 1981-12-08 Miles Laboratories, Inc. Trans-2-substituted-amido-hexahydrobenzo [A]quinolizines
US4353656A (en) * 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
FR2585563B1 (fr) * 1985-07-30 1993-11-12 Glaxo Group Ltd Dispositif pour administrer des medicaments a des patients
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2794742B1 (fr) * 1999-06-11 2005-06-03 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
EP1274706A1 (en) * 2000-04-18 2003-01-15 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
PL1638529T3 (pl) * 2003-06-16 2017-03-31 Andrx Pharmaceuticals, Llc. Kompozycja doustna o przedłużonym uwalnianiu
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (en) * 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
KR100682506B1 (ko) * 2005-01-18 2007-02-15 (주)젠크로스 프라지콴텔, 또는 이의 염을 포함하는 약학 조성물
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
RU2409365C2 (ru) 2011-01-20
KR20080030666A (ko) 2008-04-04
PT1885363E (pt) 2009-01-08
PL1885363T3 (pl) 2009-05-29
DK1885363T3 (da) 2008-12-08
AU2006268098A1 (en) 2007-01-18
DE602006002982D1 (de) 2008-11-13
EP1885363A1 (en) 2008-02-13
ZA200800905B (en) 2010-04-28
CA2615077A1 (en) 2007-01-18
SI1885363T1 (sl) 2009-02-28
EP1885363B1 (en) 2008-10-01
EP2027861B1 (en) 2011-08-31
RS50626B (sr) 2010-06-30
NZ565522A (en) 2010-04-30
ATE409481T1 (de) 2008-10-15
RU2008105590A (ru) 2009-08-20
ES2314931T3 (es) 2009-03-16
CY1108653T1 (el) 2014-04-09
HRP20080677T3 (en) 2009-02-28
US20080319000A1 (en) 2008-12-25
AU2006268098B2 (en) 2011-02-17
WO2007007105A1 (en) 2007-01-18
ATE522215T1 (de) 2011-09-15
JP2009501202A (ja) 2009-01-15
EP2027861A1 (en) 2009-02-25
GB0514501D0 (en) 2005-08-24
ME01629B (me) 2010-06-30
CN101282726A (zh) 2008-10-08

Similar Documents

Publication Publication Date Title
ZA200800905B (en) Use of 3,11B-CIS-Dihydrotetrabenazine for the treatment of symptoms of huntington's disease
HK1105893A1 (en) Compounds, compositions and methods of inhibiting a-synuclein toxicity
HK1121674A1 (en) Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer angiopoietin-2
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
IL176393A0 (en) Patterned laser treatment of the retina
WO2007012061A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
ES2414872T8 (es) Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
MY152164A (en) Extending time to disease progression or survival in cancer patients
UA94580C2 (ru) Аналог 39-дезметоксирапамицина, способный преодолевать гематоэнцефалический барьер, для лечения патологического состояния, вызванного нейрогенным повреждением или заболеванием
GB0410399D0 (en) The treatment of respiratory disease
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
GB0410398D0 (en) The treatment of respiratory disease
HK1110768A1 (en) 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
PT2366393E (pt) Roflumilaste para o tratamento da hipertensão pulmonar
DK1732648T3 (da) Sygdomsbehandling
WO2007054566A3 (en) Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy
RU2002103738A (ru) Компонент, обеспечивающий поверхностно-активные свойства композиций-аналогов препаратов для заместительной сурфактантной терапии легочных заболеваний
WO2006062973A3 (en) Use of organic compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120713